Jingwu Zhang Zang
Director/Board Member en HH&L ACQUISITION CO. .
Fortuna: 8 M $ al 31/03/2024
Perfil
Fundador de I-Mab y de I-Mab Biopharma (Shanghai) Co., Ltd., Jing Wu Zang es presidente de I-Mab y presidente y director general de I-Mab Biopharma (Shanghai) Co. (una filial de I-Mab). El Dr. Zang también forma parte del consejo de HH&L Acquisition Co. Ltd. En su trayectoria profesional anterior, el Dr. Zang fue Presidente y Director Científico de Simcere Pharmaceutical Group Ltd., Presidente y Director Científico de BioSciKin Co. Ltd., Director del Instituto de Inmunología de Shanghai de la Facultad de Medicina de la Universidad Jiaotong de Shanghai, Vicepresidente Senior, Jefe de Investigación y Desarrollo de Glaxosmithkline China Ltd., Director de Opexa Pharmaceuticals, Inc. y Profesor del Baylor College of Medicine. Jing Wu Zang se doctoró en la Universidad Jiao Tong de Shanghai y en la Vrije Universiteit Brussel.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
I-MAB
4.98% | 31/12/2023 | 9 449 021 ( 4.98% ) | 8 M $ | 31/03/2024 |
Cargos activos de Jingwu Zhang Zang
| Empresas | Cargo | Inicio |
|---|---|---|
| HH&L ACQUISITION CO. | Director/Board Member | 04/02/2021 |
I-MAB Biopharma Co., Ltd.
 I-MAB Biopharma Co., Ltd. BiotechnologyHealth Technology I-Mab Biopharma (Shanghai) Co., Ltd. engages in the development of biologics. It focuses on monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune diseases. The company was founded by Jingwu Zang in March 2017 and is headquartered in Shanghai, China. | Founder | 01/06/2016 |
Antiguos cargos conocidos de Jingwu Zhang Zang.
| Empresas | Cargo | Fin |
|---|---|---|
| I-MAB | Chief Executive Officer | 30/09/2022 |
| SIMCERE PHARMACEUTICAL GROUP LIMITED | President | 01/04/2016 |
BioSciKin Co., Ltd.
 BioSciKin Co., Ltd. Pharmaceuticals: MajorHealth Technology BioSciKin Co., Ltd. develops drugs and medical products. The private company is based in Nanjing, China. | President | 01/04/2016 |
| Glaxosmithkline China Ltd. | Chief Tech/Sci/R&D Officer | 01/06/2013 |
| Shanghai Jiao Tong University School of Medicine | Corporate Officer/Principal | 01/04/2007 |
Formación de Jingwu Zhang Zang.
| Shanghai Jiao Tong University | Doctorate Degree |
| Vrije Universiteit Brussel | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| SIMCERE PHARMACEUTICAL GROUP LIMITED | Health Technology |
| I-MAB | Health Technology |
| Empresas privadas | 7 |
|---|---|
| Opexa Pharmaceuticals, Inc. | Health Technology |
Institut Pasteur de Shanghai
 Institut Pasteur de Shanghai Miscellaneous Commercial ServicesCommercial Services Institut Pasteur de Shanghai operates as a non-profit life sciences organization. The private company is based in Shanghai, China. | Commercial Services |
| Glaxosmithkline China Ltd. | |
| The Institute of Health Sciences | |
BioSciKin Co., Ltd.
BioSciKin Co., Ltd. Pharmaceuticals: MajorHealth Technology BioSciKin Co., Ltd. develops drugs and medical products. The private company is based in Nanjing, China. | Health Technology |
I-MAB Biopharma Co., Ltd.
I-MAB Biopharma Co., Ltd. BiotechnologyHealth Technology I-Mab Biopharma (Shanghai) Co., Ltd. engages in the development of biologics. It focuses on monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune diseases. The company was founded by Jingwu Zang in March 2017 and is headquartered in Shanghai, China. | Health Technology |
HH&L Acquisition Co.
 HH&L Acquisition Co. Financial ConglomeratesFinance HH&L Acquisition Co. is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on September 4, 2020 and is headquartered in Hong Kong. | Finance |
- Bolsa de valores
- Insiders
- Jingwu Zhang Zang
